Eli Lilly can’t avoid royalties in insulin suit

21-10-2021

Alex Baldwin

Eli Lilly can’t avoid royalties in insulin suit

Jonathan Weiss / Shutterstock.com

Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies (RCT), an Arizona judge has ruled.


Eli Lilly, Insulin, Research Corporation Technologies, US District Court for the District of Arizona, Philips Petroleum Company

LSIPR